Korro reports full year 2024 financial results and provides business updates

Cambridge, mass., march 18, 2025 (globe newswire) -- korro bio, inc. (korro) (nasdaq: krro), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing rna for both rare and highly prevalent diseases, today reported full-year 2024 financial results, and provided an update on recent progress and anticipated milestones.
KRRO Ratings Summary
KRRO Quant Ranking